# Oncology pipeline: research, clinical trials and treatments

We are committed to transforming the lives of people with cancer through innovative therapies. Our robust pipeline spans cancer cell–directed and immuno-oncology investigational therapies. Through global collaboration, we are tackling some of the most challenging, but potentially most impactful, areas of cancer research.

## Latest development phase

### Filter by:
- **Development phase**
  - Phase I
  - Phase II
  - Phase III

### Cancer cell–directed

#### zongertinib (HER2 TKI) 1–11  
- [Zongertinib: Phase I](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/her2-tki#zongertinib-phase-i "Zongertinib: Phase I")  
  - Phase I  
  - Active, not recruiting

**Solid tumors (Phase Ia) and NSCLC (Phase Ib)**  
  (Recruiting for cohorts 7 and 8 only)
  
- [Zongertinib: Phase II](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/her2-tki#zongertinib-phase-ii "Zongertinib: Phase II")  
  - Phase II*  
  - Recruiting

**NSCLC, solid tumors, breast cancer, gastric adenocarcinoma, GEJ adenocarcinoma and esophageal adenocarcinoma**  
  ± combination
  
- [Zongertinib: Phase III](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/her2-tki#zongertinib-phase-iii "Zongertinib: Phase III")  
  - Phase III  
  - Recruiting  
  
  **NSCLC**

### T-cell engagers

#### obrixtamig (DLL3/CD3 T-cell engager) 12–21  
- [DLL3/CD3 T-cell engager – obrixtamig: Phase I](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/dll3-cd3-t-cell-engager#obrixtamig-phase-i "DLL3/CD3 T-cell engager – obrixtamig: Phase I")  
  - Phase I†  
  - Recruiting

**SCLC and other NECs**  
  ± combination

- [DLL3/CD3 T-cell engager – obrixtamig: Phase II](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/dll3-cd3-t-cell-engager#obrixtamig-phase-ii "DLL3/CD3 T-cell engager – obrixtamig: Phase II")  
  - Phase II  
  - Recruiting

**epNEC**

- [DLL3/CD3 T-cell engager – obrixtamig: Phase III](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/dll3-cd3-t-cell-engager#obrixtamig-phase-iii "DLL3/CD3 T-cell engager – obrixtamig: Phase III")  
  - Phase III  
  - Recruiting

**SCLC and epNEC**

#### B7-H6/CD3 T-cell engager 22,23
- [B7-H6/CD3 T-cell engager: Phase I](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/b7-h6-t-cell-engager#b7-h6-cd3-t-cell-engager-phase-i "B7-H6/CD3 T-cell engager: Phase I")  
  - Phase I  
  - Recruiting

**Solid tumors, colorectal carcinoma, gastric carcinoma and PDAC**
  ± combination

### Oncolytic viruses

#### VSV-GP oncolytic virus 24
- [VSV-GP oncolytic virus: Phase I](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/vsv-gp#vsv-gp-phase-i "VSV-GP oncolytic virus: Phase I")  
  - Phase I  
  - Recruiting

**Solid tumors**
  ± combination

### Immuno-modulators

#### CD137xFAP bsAb 25,26  
- [CD137 FAP bispecific agonist antibody: Phase I](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/cd137-fap-agonist#cd137-phase-i "CD137 FAP bispecific agonist antibody: Phase I")  
  - Phase I  
  - Active, not recruiting (Phase Ib)

**Solid tumors and HNSCC**  
  ± combination

- [SIRPα Antagonist](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/sirpa-antagonist "SIRPα Antagonist")  
  - Phase I  
  - Recruiting

**Solid tumors and HNSCC**  
  (Recruiting for Phase Ib)
  ± combination

- [2nd generation STING agonist](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/sting-agonist "2nd generation STING agonist")  
  - Phase I  
  - Recruiting

**Solid tumors**
  + combination

- [Immunological fusion protein](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/immunological-fusion-protein "Immunological fusion protein")  
  - Phase I  
  - Recruiting

**Solid tumors**

- [ezabenlimab (PD-1 inhibitor) 14,22,24,26,27,30](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/ezabenlimab "ezabenlimab")  
- [ezabenlimab: Phase I](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/ezabenlimab#ezabenlimab-phase-i "ezabenlimab: Phase I")  
  - Phase I†  
  - Recruiting

**Solid tumors, PDAC, SCLC and other NECs**
  + combination

### Download a summary of ongoing clinical trials  
- [Download](https://pro.boehringer-ingelheim.com/inoncology/bipdf/asco-2026-clinical-trials-handout "Download")

### References

- Heymach JV, et al. _J Clin Oncol_ 2025;43(11):1337–1347.
- Heymach JV, et al. _N Engl J Med_ 2025;392(23):2321–2333.
- ClinicalTrials.gov. NCT04886804. [https://clinicaltrials.gov/study/NCT04886804](https://clinicaltrials.gov/study/NCT04886804 "clinicaltrials.gov NCT04886804") (Accessed: May 2026).
- ClinicalTrials.gov. NCT06151574. [https://clinicaltrials.gov/study/NCT06151574](https://clinicaltrials.gov/study/NCT06151574 "clinicaltrials.gov NCT06151574") (Accessed: April 2026).
- ClinicalTrials.gov. NCT06581432. [https://clinicaltrials.gov/study/NCT06581432](https://clinicaltrials.gov/study/NCT06581432 "clinicaltrials.gov NCT06581432") (Accessed: April 2026).
- Schram AM, et al. _J Clin Oncol_ 2025;43(16_suppl). Abstract TPS3187.
- ClinicalTrials.gov. NCT06324357. [https://clinicaltrials.gov/study/NCT06324357](https://clinicaltrials.gov/study/NCT06324357 "clinicaltrials.gov NCT06324357") (Accessed: April 2026).
- Nakayama I, et al. _J Clin Oncol_ 2025;43(4_suppl). Abstract TPS509.
- Hurvitz SA, et al. _ESMO Open_ 2025;10(S4). Abstract 409TiP.
- ClinicalTrials.gov. NCT07486817. [https://clinicaltrials.gov/study/NCT07486817](https://clinicaltrials.gov/study/NCT07486817 "https://clinicaltrials.gov/study/NCT07486817") (Accessed: April 2026).
- ClinicalTrials.gov. NCT07195695. [https://clinicaltrials.gov/study/NCT07195695](https://clinicaltrials.gov/study/NCT07195695 "https://clinicaltrials.gov/study/NCT07195695") (Accessed: April 2026).
- ClinicalTrials.gov. NCT04429087. [https://clinicaltrials.gov/study/NCT04429087](https://clinicaltrials.gov/study/NCT04429087 "https://clinicaltrials.gov/study/NCT04429087") (Accessed: April 2026).
- Wermke M, et al. _J Clin Oncol_ 2025;43(27):3021–3031.
- ClinicalTrials.gov. NCT05879978. [https://clinicaltrials.gov/study/NCT05879978](https://clinicaltrials.gov/study/NCT05879978 "clinicaltrials.gov NCT05879978") (Accessed: April 2026).
- ClinicalTrials.gov. NCT05882058. [https://clinicaltrials.gov/study/NCT05882058](https://clinicaltrials.gov/study/NCT05882058 "clinicaltrials.gov NCT05882058") (Accessed: April 2026).
- ClinicalTrials.gov. NCT06132113. [https://clinicaltrials.gov/study/NCT06132113](https://clinicaltrials.gov/study/NCT06132113 "clinicaltrials.gov NCT06132113") (Accessed: April 2026).
- ClinicalTrials.gov. NCT06077500. [https://clinicaltrials.gov/study/NCT06077500](https://clinicaltrials.gov/study/NCT06077500 "clinicaltrials.gov NCT06077500") (Accessed: April 2026).
- ClinicalTrials.gov. NCT05990738. [https://clinicaltrials.gov/study/NCT05990738](https://clinicaltrials.gov/study/NCT05990738 "clinicaltrials.gov NCT05990738") (Accessed: April 2026).
- Wermke M, et al. ASCO 2025. Poster 8094.
- ClinicalTrials.gov. NCT07544654. [https://clinicaltrials.gov/study/NCT07544654](https://clinicaltrials.gov/study/NCT07544654 "https://clinicaltrials.gov/study/NCT07544654") (Accessed: May 2026).
- ClinicalTrials.gov. NCT07472517. [https://clinicaltrials.gov/study/NCT07472517](https://clinicaltrials.gov/study/NCT07472517 "https://clinicaltrials.gov/study/NCT07472517") (Accessed: April 2026).
- ClinicalTrials.gov. NCT06091930. [https://clinicaltrials.gov/study/NCT06091930](https://clinicaltrials.gov/study/NCT06091930 "clinicaltrials.gov NCT06091930") (Accessed: April 2026).
- ClinicalTrials.gov. NCT06882746. [https://clinicaltrials.gov/study/NCT06882746](https://clinicaltrials.gov/study/NCT06882746 "clinicaltrials.gov NCT06882746") (Accessed: April 2026).
- ClinicalTrials.gov. NCT05155332. [https://clinicaltrials.gov/study/NCT05155332](https://clinicaltrials.gov/study/NCT05155332 "https://clinicaltrials.gov/study/NCT05155332") (Accessed: April 2026).
- Shroff RT, et al. _Cancer Res_ 2025;85(8_Supplement_2). Abstract CT110.
- ClinicalTrials.gov. NCT04958239. [https://clinicaltrials.gov/study/NCT04958239](https://clinicaltrials.gov/study/NCT04958239 "clinicaltrials.gov NCT04958239") (Accessed: April 2026).
- ClinicalTrials.gov. NCT05327946. [https://clinicaltrials.gov/study/NCT05327946](https://clinicaltrials.gov/study/NCT05327946 "clinicaltrials.gov NCT05327946") (Accessed: April 2026).
- Wang JS, et al. _J Clin Oncol_ 2025;43(16_suppl). Abstract 2515.
- ClinicalTrials.gov. NCT06806852. [https://clinicaltrials.gov/study/NCT06806852](https://clinicaltrials.gov/study/NCT06806852 "clinicaltrials.gov NCT06806852") (Accessed: April 2026).
- ClinicalTrials.gov. NCT05471856. [https://clinicaltrials.gov/study/NCT05471856](https://clinicaltrials.gov/study/NCT05471856 "clinicaltrials.gov NCT05471856") (Accessed: April 2026).
- ClinicalTrials.gov. NCT07224425. [https://clinicaltrials.gov/study/NCT07224425](https://clinicaltrials.gov/study/NCT07224425 "https://clinicaltrials.gov/study/NCT07224425") (Accessed: April 2026).

bsAb, bispecific antibody; CD, cluster of differentiation; DLL3, delta-like ligand 3; epNEC, extrapulmonary neuroendocrine carcinoma; FAP, fibroblast activation protein; GEJ, gastroesophageal junction; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; NEC, neuroendocrine carcinoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; PDAC, pancreatic ductal adenocarcinoma; SCLC, small cell lung cancer; SIRPα, signal-regulatory protein alpha; STING, small molecule agonist of the stimulator of interferon genes; TKI, tyrosine kinase inhibitor; VSV, vesicular stomatitis virus.